Idenix Pharma Initiates Phase II Study - Analyst Blog

By
A A A

Idenix Pharmaceuticals, Inc. ( IDIX ) recently announced that it has initiated a phase II study (HELIX-1: n = 90) evaluating the combination of hepatitis C virus (HCV) infection candidates, samatasvir (IDX719) and simeprevir (TMC435). The study is being conducted in collaboration with Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson ( JNJ ).

As monotherapy, samatasvir is being developed by Idenix Pharma and simeprevir by Johnson & Johnson in collaboration with Medivir AB.

The 12-week, randomized, double-blind and parallel group HELIX-1 study will evaluate three doses of samatasvir (50, 100, or 150 mg). The study will assess the safety and tolerability of samatasvir in combination with simeprevir and ribavirin, a widely used HCV infection drug in first-line non-cirrhotic, genotype 1b or 4 HCV-infected patients.

We remind investors that Idenix Pharma entered into a non-exclusive collaboration agreement with Johnson & Johnson, in Jan 2013, to develop HCV combination therapies. The collaboration will assess different combinations of samatasvir, simeprevir, and TMC647055 (another Johnson & Johnson's HCV candidate).

As per the terms of the agreement, Idenix Pharma will conduct the studies, while Johnson & Johnson will supply simeprevir and TMC647055 for the trials free of cost.  Both the companies will not receive any milestone and royalty payments as a part of the agreement.

Idenix Pharma plans to initiate a second phase II trial (HELIX-2) on samatasvir, simeprevir and TMC647055 in the second half of 2013.

A sizeable population suffers from HCV the world over. However, the treated population is much lower. This leaves the field open for new treatments.

Both Idenix Pharma and Johnson & Johnson, currently carry a Zacks Rank #3 (Hold). Right now, companies that look well-positioned include Zacks Ranked #1 (Strong Buy) Jazz Pharmaceuticals ( JAZZ ) and Salix Pharmaceuticals, Ltd. ( SLXP ).



IDENIX PHARMA (IDIX): Free Stock Analysis Report

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

JOHNSON & JOHNS (JNJ): Free Stock Analysis Report

SALIX PHARM-LTD (SLXP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: IDIX , JAZZ , JNJ , SLXP

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

100,376,898
  • $17.62 ▲ 0.51%
83,231,837
  • $25.62 ▲ 1.91%
75,739,329
  • $111.78 ▼ 0.77%
65,297,937
  • $36.37 ▼ 1.76%
59,053,093
  • $47.66 ▲ 0.29%
53,482,350
  • $2.59 ▼ 0.38%
51,504,284
  • $7.34 ▲ 2.37%
51,434,656
  • $8.14 ▲ 6.96%
As of 12/19/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com